<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03417258</url>
  </required_header>
  <id_info>
    <org_study_id>Policlinic Hospital, Bari</org_study_id>
    <nct_id>NCT03417258</nct_id>
  </id_info>
  <brief_title>Phytoestrogens and Colonic Adenomatous Polyps</brief_title>
  <acronym>FITOPOL</acronym>
  <official_title>Bioavailability of Phytoestrogens and Prevalence of Adenomatous Polyps in Human Colon</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Bari</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Bari</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      INTRODUCTION: The data obtained by experimental studies about the influence of phytoestrogens
      on colorectal cancer (CRC) have been very promising. On the other hand, clinical trials have
      produced conflicting results. The literature suggests that some subclasses of phytoestrogens
      may have protective effects against CRC and colon adenomas, but most of these results come
      from population studies based on the dietary intake of phytoestrogens. On these premises, it
      is possible to hypothesize that the variability of the data reported in the literature may be
      due to the fact that the real absorption of phytoestrogens (by assessing their concentration
      in the serum or urine) and/or the ability of the single individual of producing equol was not
      evaluated.

      PURPOSE: In the present study, the association between the phytoestrogens intake and the
      prevalence of colon adenomas was evaluated not only on the basis of the simply dietary intake
      but also on the measurement their intestinal absorption. Moreover, a specific evaluation of
      equol production by the intestinal flora was performed. Finally, intestinal bacteria involved
      in equol production were evaluated.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      MATERIALS AND METHODS: Patients with sporadic colon adenomas were enrolled in group I (case)
      and patients without sporadic colorectal adenomas matched for sex, age and BMI were enrolled
      in group II (control). All participants underwent the following evaluations: BMI, dietary
      history (for quantitative and qualitative analysis of dietary habits), quantitative analysis
      of phytoestrogens (by dietary questionnaires), medications (chronic assumption of aspirin at
      low doses), characteristics of the polyps (for a calculation the cancer risk), analysis of
      urinary excretion of phytoestrogens [by high pressure liquid chromatography (HPLC)] and
      intestinal flora [by mass spectrometry with Matrix Assisted Laser Desorption Ionization
      Time-of-Flight (MALDI-TOF) technology]. At the enrolment, patients will be invited to assume
      a standard quantitative of phytoestrogens at 8:00 a.am. and collect both a fecal sample and
      the urine of the following 24 hrs.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 15, 2016</start_date>
  <completion_date type="Actual">April 24, 2019</completion_date>
  <primary_completion_date type="Actual">June 15, 2017</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <target_duration>1 Day</target_duration>
  <primary_outcome>
    <measure>Phytoestrogen absorption</measure>
    <time_frame>one day</time_frame>
    <description>It will be evaluated on the basis of their 24h urine excretion</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Intestinal microbiota</measure>
    <time_frame>one day</time_frame>
    <description>It will be evaluated on fecal samples</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">30</enrollment>
  <condition>Intestinal Polyps</condition>
  <arm_group>
    <arm_group_label>Patients with polyps</arm_group_label>
    <description>urinary phytoestrogen excretion and intestinal microbiota evaluation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Patients without polyps</arm_group_label>
    <description>urinary phytoestrogen excretion and intestinal microbiota evaluation</description>
  </arm_group>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Urine, feces
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        All patients (aged between 50 and 75 years) undergoing colonoscopy within 3 months from the
        study evaluation.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  subjects of both sexes aged between 50 and 75 years

          -  colonoscopy within 3 months from the study evaluation

        Exclusion Criteria:

          -  age &lt; 50 and &gt; 75 years

          -  previous diagnosis of colon cancer or inflammatory bowel diseases (IBD)

          -  Hereditary intestinal tumors (FAP, HNPCC, ...)

          -  ongoing infections

          -  intake, in the last 4 weeks, of drugs that alter the intestinal bacterial flora

          -  creatinine clearance below 60 ml/min

          -  liver failure
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Alfredo Di Leo</last_name>
    <role>Study Chair</role>
    <affiliation>University of Bari</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Policlinic Hospital</name>
      <address>
        <city>Bari</city>
        <zip>70124</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <reference>
    <citation>Xu X, Harris KS, Wang HJ, Murphy PA, Hendrich S. Bioavailability of soybean isoflavones depends upon gut microflora in women. J Nutr. 1995 Sep;125(9):2307-15.</citation>
    <PMID>7666247</PMID>
  </reference>
  <reference>
    <citation>Atkinson C, Frankenfeld CL, Lampe JW. Gut bacterial metabolism of the soy isoflavone daidzein: exploring the relevance to human health. Exp Biol Med (Maywood). 2005 Mar;230(3):155-70. Review.</citation>
    <PMID>15734719</PMID>
  </reference>
  <reference>
    <citation>Jin H, Leng Q, Li C. Dietary flavonoid for preventing colorectal neoplasms. Cochrane Database Syst Rev. 2012 Aug 15;(8):CD009350. doi: 10.1002/14651858.CD009350.pub2. Review.</citation>
    <PMID>22895989</PMID>
  </reference>
  <reference>
    <citation>Kocic B, Kitic D, Brankovic S. Dietary flavonoid intake and colorectal cancer risk: evidence from human population studies. J BUON. 2013 Jan-Mar;18(1):34-43. Review.</citation>
    <PMID>23613386</PMID>
  </reference>
  <reference>
    <citation>Setchell KD, Brown NM, Lydeking-Olsen E. The clinical importance of the metabolite equol-a clue to the effectiveness of soy and its isoflavones. J Nutr. 2002 Dec;132(12):3577-84. Review.</citation>
    <PMID>12468591</PMID>
  </reference>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>January 18, 2018</study_first_submitted>
  <study_first_submitted_qc>January 24, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">January 31, 2018</study_first_posted>
  <last_update_submitted>March 26, 2020</last_update_submitted>
  <last_update_submitted_qc>March 26, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 30, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Bari</investigator_affiliation>
    <investigator_full_name>Michele Barone</investigator_full_name>
    <investigator_title>Researcher</investigator_title>
  </responsible_party>
  <keyword>phytoestrogens</keyword>
  <keyword>isoflavones</keyword>
  <keyword>adenomatous polyps</keyword>
  <keyword>microbiome</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adenomatous Polyps</mesh_term>
    <mesh_term>Polyps</mesh_term>
    <mesh_term>Intestinal Polyps</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol, Statistical Analysis Plan, and Informed Consent Form</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>Yes</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>January 24, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/58/NCT03417258/Prot_SAP_ICF_003.pdf</document_url>
    </provided_document>
  </provided_document_section>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

